ondansetron has been researched along with fluorouracil in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (47.22) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 8 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R | 1 |
| Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M | 1 |
| Adenis, A; Bonneterre, J; Hebbar, M; Hecquet, B; Lecomte, S; Pion, JM; Vanlemmens, L | 1 |
| Bjurstrom, T; Bozigian, HP; Gooding, AE; Griffin, RH; Hansen, LA; Hsyu, PH; Huang, AT; Mitchell, R; Panella, TL; Pritchard, JF | 1 |
| Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D | 1 |
| Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L | 1 |
| Barrenetxea, G; Centeno, MM; de la Rica, M; Rodríguez-Escudero, FJ; Romero, H; Schneider, J | 1 |
| Ionta, MT; Massidda, B | 1 |
| Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS | 1 |
| du Bois, A; Holy, R; Kriesinger-Schröder, H; Vach, W | 1 |
| Kobayashi, S; Kumai, T; Nakura, H; Tanaka, M; Tateishi, T; Watanabe, M | 1 |
| Adachi, I; Fujimaki, M; Horikoshi, I; Kobayashi, F; Sakamoto, T; Sato, H; Shimizu, T; Yamanouchi, T | 1 |
| Fukui, H; Hoshino, K; Ikeda, M; Kawaguchi, H; Kimura, O; Ono, K | 1 |
| Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H | 1 |
| Fox, JL; Lucas, DS; Prince, RA | 1 |
| Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J | 1 |
| Bando, K; Hagiwara, N; Ikeda, K; Kiyama, T; Miyashita, M; Onda, M; Saito, T; Sasajima, K; Tsuchiya, Y; Yamashita, K; Yoshiyuki, T | 1 |
| Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T | 1 |
| Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S | 1 |
| Raina, V; Sharma, A | 1 |
| Hayakawa, H; Ishida, T; Kusaba, T | 1 |
| Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS | 1 |
| Chang, HK; Chen, JS; Huang, JS; Liau, CT; Liaw, CC; Lin, YC | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY | 1 |
| McEvilly, M; Popelas, C; Tremmel, B | 1 |
| Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L | 1 |
| Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M | 1 |
| Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S | 1 |
1 review(s) available for ondansetron and fluorouracil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
16 trial(s) available for ondansetron and fluorouracil
| Article | Year |
|---|---|
Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Imidazoles; Methotrexate; Middle Aged; Ondansetron; Vomiting | 1991 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Imidazoles; Infusions, Intravenous; Metoclopramide; Middle Aged; Nausea; Ondansetron; Randomized Controlled Trials as Topic; Time Factors; Vomiting | 1990 |
Oral ondansetron pharmacokinetics: the effect of chemotherapy.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; Cisplatin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Male; Neoplasms; Ondansetron; Tablets | 1994 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Double-Blind Method; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Nausea; Ondansetron; Prospective Studies; Vomiting | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Metoclopramide; Middle Aged; Nausea; Ondansetron; Regression Analysis; Vomiting | 1993 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Metoclopramide; Ondansetron; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Vomiting | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granisetron; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Injections, Intravenous; Methotrexate; Middle Aged; Ondansetron; Serotonin Antagonists; Tropisetron; Vomiting | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Nausea; Ondansetron; Serotonin Antagonists; Treatment Outcome; Vomiting | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Incidence; Middle Aged; Ondansetron; Selective Serotonin Reuptake Inhibitors; Vomiting | 1996 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Male; Middle Aged; Nausea; Ondansetron; Stomach Neoplasms; Suppositories; Vomiting | 1997 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Injections, Intravenous; Middle Aged; Nausea; Ondansetron; Tablets; Vomiting | 1998 |
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Ondansetron; Prospective Studies; Transplantation Conditioning | 1998 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Metoclopramide; Middle Aged; Ondansetron; Prospective Studies; Vomiting | 2000 |
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Kidney Diseases; Kidney Function Tests; Leukopenia; Male; Malonates; Metabolic Clearance Rate; Metoclopramide; Middle Aged; Ondansetron; Organoplatinum Compounds; Proteinuria; Stomach Neoplasms; Survival Analysis; Vomiting | 2002 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Dexamethasone; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Ondansetron; Sex Factors; Vomiting | 2003 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Ondansetron; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome | 2012 |
19 other study(ies) available for ondansetron and fluorouracil
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Male; Nausea; Ondansetron; Tablets; Treatment Outcome; Vomiting | 1995 |
The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists.
Topics: Animals; Antiemetics; Antimetabolites, Antineoplastic; Biotransformation; Bridged Bicyclo Compounds, Heterocyclic; Cytosol; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Granisetron; Indoles; Liver; Male; Ondansetron; Oxazines; Oxidoreductases; Quinolizines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Tropisetron | 1996 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Prognosis; Remission Induction; Vomiting | 1997 |
Effect of a dual-lumen peripheral catheter on the delivery of known incompatible medications.
Topics: Aminophylline; Ampicillin; Blood Proteins; Catheterization, Peripheral; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Fluorouracil; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Infusion Pumps, Implantable; Infusions, Intravenous; Ondansetron; Sodium Bicarbonate | 1998 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Nausea; Ondansetron; Vomiting, Anticipatory | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Nausea; Ondansetron; Stomach Neoplasms; Time Factors; Vomiting, Anticipatory | 2000 |
Generalised seizures following ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Ondansetron; Seizures | 2001 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Nausea; Ondansetron; Vomiting, Anticipatory | 2002 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; Metoclopramide; Middle Aged; Nausea; Ondansetron; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Vomiting | 2009 |
Use of uridine triacetate for the management of fluorouracil overdose.
Topics: Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Overdose; Fluorouracil; Home Infusion Therapy; Humans; Leucovorin; Male; Medication Errors; Middle Aged; Ondansetron; Organoplatinum Compounds; Uridine | 2011 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; Colonic Neoplasms; Cytokines; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Gastrointestinal Agents; Gene Expression Regulation; Immunosuppressive Agents; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mucositis; Ondansetron; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2013 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease Resistance; Droperidol; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Mastectomy; Methotrexate; Metoclopramide; Middle Aged; Models, Biological; Narcotics; Nausea; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies; Risk Factors; Vomiting | 2013 |